Cargando…

Safety of potassium-bearing citrate in patients with renal transplantation: A case report

RATIONALE: Urinary lithiasis is one of severe postoperative complications in patients undergoing renal transplantation, possibly leading to anuria, urinary infection, or even acute renal failure. Potassium sodium hydrogen citrate (PSHC), a potassium-bearing citrate, is commonly prescribed to prevent...

Descripción completa

Detalles Bibliográficos
Autores principales: Wang, Lin, Cui, Yinglin, Zhang, Jianwei, Zhang, Qinsheng
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Wolters Kluwer Health 2017
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5662332/
https://www.ncbi.nlm.nih.gov/pubmed/29049166
http://dx.doi.org/10.1097/MD.0000000000006933
_version_ 1783274619992539136
author Wang, Lin
Cui, Yinglin
Zhang, Jianwei
Zhang, Qinsheng
author_facet Wang, Lin
Cui, Yinglin
Zhang, Jianwei
Zhang, Qinsheng
author_sort Wang, Lin
collection PubMed
description RATIONALE: Urinary lithiasis is one of severe postoperative complications in patients undergoing renal transplantation, possibly leading to anuria, urinary infection, or even acute renal failure. Potassium sodium hydrogen citrate (PSHC), a potassium-bearing citrate, is commonly prescribed to prevent stone formation. PATIENT CONCERNS: A 25-year-old man (patient 1) and a 31-year-old man (patient 2) receiving renal transplantation for end-stage renal disease (ESRD) were enrolled in this study. They were given 10 g/day of PSHC granules from the ninth day to the 17th day after surgery. Patient 1 presented chest tightness, nausea, muscle weakness, and ascending paralysis on the 10th day. Patient 2 presented weak waves on EGG on the 17th day. Moreover, their serum potassium concentrations (SPCs) were 7.67 and 6.05 mmol/L, respectively. DIAGNOSIS: Acute hyperkalemia. INTERVENTIONS: Hemo-filtration was performed for patient 1, while patient 2 received 10% calcium gluconate 10 mL, 5% NaHCO(3) 125 mL, and 10% glucose 500 mL with the addition of 10 units of insulin through intravenous drip. OUTCOMES: Their SPCs dropped to the normal range. LESSONS: Physicians should pay close attentions to potential risks caused by PSHC, and monitor the SPCs to minimize the occurrence of hyperkalemia.
format Online
Article
Text
id pubmed-5662332
institution National Center for Biotechnology Information
language English
publishDate 2017
publisher Wolters Kluwer Health
record_format MEDLINE/PubMed
spelling pubmed-56623322017-11-21 Safety of potassium-bearing citrate in patients with renal transplantation: A case report Wang, Lin Cui, Yinglin Zhang, Jianwei Zhang, Qinsheng Medicine (Baltimore) 5200 RATIONALE: Urinary lithiasis is one of severe postoperative complications in patients undergoing renal transplantation, possibly leading to anuria, urinary infection, or even acute renal failure. Potassium sodium hydrogen citrate (PSHC), a potassium-bearing citrate, is commonly prescribed to prevent stone formation. PATIENT CONCERNS: A 25-year-old man (patient 1) and a 31-year-old man (patient 2) receiving renal transplantation for end-stage renal disease (ESRD) were enrolled in this study. They were given 10 g/day of PSHC granules from the ninth day to the 17th day after surgery. Patient 1 presented chest tightness, nausea, muscle weakness, and ascending paralysis on the 10th day. Patient 2 presented weak waves on EGG on the 17th day. Moreover, their serum potassium concentrations (SPCs) were 7.67 and 6.05 mmol/L, respectively. DIAGNOSIS: Acute hyperkalemia. INTERVENTIONS: Hemo-filtration was performed for patient 1, while patient 2 received 10% calcium gluconate 10 mL, 5% NaHCO(3) 125 mL, and 10% glucose 500 mL with the addition of 10 units of insulin through intravenous drip. OUTCOMES: Their SPCs dropped to the normal range. LESSONS: Physicians should pay close attentions to potential risks caused by PSHC, and monitor the SPCs to minimize the occurrence of hyperkalemia. Wolters Kluwer Health 2017-10-20 /pmc/articles/PMC5662332/ /pubmed/29049166 http://dx.doi.org/10.1097/MD.0000000000006933 Text en Copyright © 2017 the Author(s). Published by Wolters Kluwer Health, Inc. http://creativecommons.org/licenses/by-nc/4.0 This is an open access article distributed under the terms of the Creative Commons Attribution-Non Commercial License 4.0 (CCBY-NC), where it is permissible to download, share, remix, transform, and buildup the work provided it is properly cited. The work cannot be used commercially without permission from the journal. http://creativecommons.org/licenses/by-nc/4.0
spellingShingle 5200
Wang, Lin
Cui, Yinglin
Zhang, Jianwei
Zhang, Qinsheng
Safety of potassium-bearing citrate in patients with renal transplantation: A case report
title Safety of potassium-bearing citrate in patients with renal transplantation: A case report
title_full Safety of potassium-bearing citrate in patients with renal transplantation: A case report
title_fullStr Safety of potassium-bearing citrate in patients with renal transplantation: A case report
title_full_unstemmed Safety of potassium-bearing citrate in patients with renal transplantation: A case report
title_short Safety of potassium-bearing citrate in patients with renal transplantation: A case report
title_sort safety of potassium-bearing citrate in patients with renal transplantation: a case report
topic 5200
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5662332/
https://www.ncbi.nlm.nih.gov/pubmed/29049166
http://dx.doi.org/10.1097/MD.0000000000006933
work_keys_str_mv AT wanglin safetyofpotassiumbearingcitrateinpatientswithrenaltransplantationacasereport
AT cuiyinglin safetyofpotassiumbearingcitrateinpatientswithrenaltransplantationacasereport
AT zhangjianwei safetyofpotassiumbearingcitrateinpatientswithrenaltransplantationacasereport
AT zhangqinsheng safetyofpotassiumbearingcitrateinpatientswithrenaltransplantationacasereport